Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Serdexmethylphenidate
open-in-new
<p>Serdexmethylphenidate is a <a href="/facts/Prodrug/cg0GNhH0">prodrug</a> of <a href="/facts/Dexmethylphenidate/lfTTXJXo">dexmethylphenidate</a> created by the pharmaceutical company Zevra Therapeutics. The compound was first approved by the FDA as one of the active ingredients in <a href="/facts/Azstarys/phYSgPbB">Azstarys</a> for the treatment of <a href="/facts/Attention_deficit_hyperactivity_disorder/uSqjIyhd">attention deficit hyperactivity disorder</a> (ADHD) in children, adolescents, and adults in March 2021. Serdexmethylphenidate is a prodrug which has a delayed <a href="/facts/Onset_of_action/BTIWvLSY">onset of action</a> and a prolonged duration of effects compared to dexmethylphenidate, its parent compound. </p>